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We compared E6/E7 protein properties of three different HPV-16 variants: AA, E-P and E-350G. Primary
human foreskin keratinocytes (PHFK) were transduced with HPV-16 E6 and E7 and evaluated for
proliferation and ability to grow in soft agar. E-P infected keratinocytes presented the lowest efﬁciency
in colony formation. AA and E-350G keratinocytes attained higher capacity for in vitro transformation.
We observed similar degradation of TP53 among HPV-16 variants. Furthermore, we accessed the
expression proﬁle in early (p5) and late passage (p30) transduced cells of 84 genes commonly involved
in carcinogenesis. Most differences could be attributed to HPV-16 E6/E7 expression. In particular, we
detected different expression of ITGA2 and CHEK2 in keratinocytes infected with AA and AA/E-350G late
passage cells, respectively, and higher expression of MAP2K1 in E-350G transduced keratinocytes. Our
results indicate differences among HPV-16 variants that could explain, at least in part, differences in
oncogenic potential attributed to these variants.
& 2012 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Cervical cancer is one of the leading causes of women death in
developing countries (Ferlay et al., 2010). Infection by a subset of
human papillomavı´rus (HPV) types, designated high-risk HPV, is
responsible for the development of the majority, if not all, cervical
cancers. Among these, HPV-16 is the most prevalent type and
accounts for more than half of the cases (Walboomers et al.,
1999). Nevertheless, a large amount of women is just transiently
infected by HPV-16, and only a small proportion of individuals
persistently infected develop cervical lesions that may progress to
cancer (IARC, 2007). This implies further viral and host factors
that could inﬂuence the natural history of HPV infections.
HPV taxonomy is based on L1 late gene sequence variability.
Viral genomes are classiﬁed as new HPV types when they present
less than 90% of similarity in the L1 gene sequence to any other
type previously characterized. In addition, differences in homol-
ogy of less than 2% within the L1 gene characterize HPV molecular
variants (de Villiers et al., 2004). Viral variants arise mostly by
nucleotide substitutions within few restricted positions in theResearch, R. Jo ~ao Juli~ao, 245,
1 2189 5036.
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lsevier OA license.coding region of the genome; in the noncoding region, variation
may be as high as 5% among HPV variants (Bernard, 2002).
The analysis of a fragment of the LCR (long control region)
sequence of HPV-16 infected cervical samples gathered world-
wide categorized viral variants in ﬁve phylogenetic related
lineages: European (E), Asian–American (AA), Asian (As),
African-1 (Af-1) and African-2 (Af-2) (Ho et al., 1993; Chen
et al., 2005). The prevalence of molecular variants from each
branch in different geographical areas varies signiﬁcantly and
correlates with the intrinsic admixture level of each population
(Sichero and Villa, 2006).
The association of non-E variants of HPVs 16 and 18 with an
increased risk of developing cervical intraepithelial lesion (CIN)
was observed in several studies in Brasil and the United States
(Sichero et al., 2007; Xi et al., 2007). Moreover, compared to
normal smears a higher prevalence of AA variants was found in
cervical carcinoma samples from Costa Rica and Mexico
(Berumen et al., 2001; Hildesheim et al., 2001). In contrast, among
more homogeneous European populations, in which E variants
are mostly detected, the association between non-E variants
infection and higher risk of cervical disease is not observed. Yet,
infection by E variants harboring the HPV-16 E6 gene substitution
350T-G (E-350G) was suggested as an additional risk factor for
persistent infection and cytological progression to CIN grade 2/3
and squamous cell carcinoma (SCC) (Londesborough et al., 1996;
Zehbe et al., 1998). This mutation leads to a substitution
in residue 83 of the E6 protein from a leucine to a valine (L83V).
Table 1
Nucleotide and aminoacidic sequence variation among HPV-16 molecular var-
iants. E6 and E7 nucleotide and aminoacidic positions where variations were
detected relative to the prototype are depicted. Positions at which no variations
were found relative to the prototype are marked with periods. Variants are deﬁned
as previously described (Yamada et al., 1995). Aminoacid changes are indicated in
parenthesis. nt pos.–nucleotide position and aa–aminoacid.
nt position E-P aa E-P AA E-350G
E6 109T 2 Phe . .
132G 10 Arg . .
143C 14 Gln . .
145 G 14 Gln T (His) .
286 T 61 Ala A .
289 A 62 Val G .
335C 78 His T (Tyr) .
350T 83 Leu G (Val) G (Val)
403A 100 Leu . .
532A 143 Ser G .
E7 607C 16 Gln . .
647A 29 Asn . .
732T 57 Phe C .
789T 76 Ile C .
795T 78 Thr G .
Table 2
Colony formation assay and extended life span of PHFK expressing E6/E7 of
different HPV-16 molecular variants. PHFKs were transduced with the different
molecular variants of HPV-16 in three independent experiments. Cells from all
infections were seeded at low density in order to assay for colony formation
efﬁciency. Colonies were isolated and repeatedly passaged 1:6 until senescence or
when passage 30 was reached and considered immortalized. ND–not done.
Mean n cols
inf 1
Mean n cols
inf 2
Mean n cols
inf 3
mean Immortalized
cols
PHFK 9 ND ND 9 0/6
pLXSN
empty
0 ND ND 0 0/6
16 E-P 58 41 74 58 7/9
16 AA 85 61 86 77 8/8
16
E-350G
82 69 81 77 9/9
L. Sichero et al. / Virology 432 (2012) 127–132128The E-350G (or L83V) mutation is also detected among all AA but
not in Af variants (Yamada et al., 1995). Even though, the E-350G
variant was not evidently associated with cervical cancer develop-
ment in all European populations (Bontkes et al., 1998; van Duin
et al., 2000). The higher association of AA and E-350G variants and
cancer risk may be linked to a better capacity of evading from the
host immune system and/or increased oncogenic potential asso-
ciated to intrinsic biological properties of viral proteins.
The HPV genome region sufﬁcient for primary human foreskin
keratinocytes (PHFK) immortalization maps to the LCR and E6 and
E7 early genes (Villa and Schlegel, 1991). E6 and E7 proteins of high
risk HPV types are known to cooperate in the immortalization of
primary keratinocytes and to abrogate differentiation of these cells
induced by serum and calcium (Hawley-Nelson et al., 1989; Stanley,
2010). HPV E6 and E7 proteins bind to diverse cellular proteins, of
which the best studied are the association and degradation of TP53
and pRB, respectively (Mu¨nger et al., 1989; Scheffner et al., 1993).
Changes in cellular targets of E6 and E7 are shown to inﬂuence
the carcinogenic process. Functional studies demonstrate that the
E-350G E6 variant has biological advantages over the E-P
(European-Prototype) including increased TP53 degradation and
higher ability to abrogate PHFKs differentiation induced by serum
and calcium (Asadurian et al., 2007; Sto¨ppler et al., 1996), immor-
talization and transformation abilities (Richard et al., 2010), regula-
tion of tumorigenesis by the NOTCH and RAS signaling pathways
(Chakrabarti et al., 2004), degradation of BAX and binding to E6BP
(Lichtig et al., 2006). Furthermore, proteomic analysis showed
substantial difference in cellular metabolic enzyme patterns
between PHFKs transduced with HPV-16 E-P and AA variants
suggesting a mechanism underlying the greater prevalence of the
AA variant in cervical cancer (Richard et al., 2010).
In the present study, we achieved the ability of three different
HPV-16 E6 variants to immortalize primary human foreskin kerati-
nocytes using a colony formation efﬁciency assay. In addition,
individual clones were continually passaged until senescence or
passage 30 so as to score for immortalization. Transformation
capability was assessed by an anchorage independent cell growth
assay. Furthermore, RT-PCR superarray analysis was conducted to
evaluate the expression proﬁle of 84 selected cellular genes involved
in transformation and tumorigenesis which could shed light on
pathways that may be involved in the differences observed. Our
study substantiates the higher carcinogenic potential of L83V
harboring variants (AA and E-350G) which could explain the
association of these genomes to increased risk of cervical neoplasia
and highlights the importance of their geographic distribution for
cervical cancer risk assessment.Results
Variability among HPV-16 E6/E7 molecular variants
HPV-16 variants selected were previously characterized in
cervical samples from women participating in a large prospective
study (Sichero et al., 2007). We PCR-ampliﬁed a 754bp fragment
of the HPV-16 genome consisting of the complete E6/E7
sequences. Maximum divergence comprised 3 E6 aminoacids
between AA and E-P variants. All E7 nucleotide substitutions
were conservative (Table 1).
Molecular variants of HPV-16 differ in their ability to immortalize
and extend the life span of primary Human keratinocytes
PHFKs transducing HPV-16 E6/E7 at passage 6 were evaluated
for colony formation efﬁciency. Infected PHFKs reached passage
6 on average in 21 days for all variants analyzed. As expected thelifespan of normal PHFKs is limited; they undergo senescence
after few passages. Therefore, cells infected with the empty vector
and non-infected keratinocytes were independently pooled at
passage 4 for these experiments. At this time point, we conﬁrmed
HPV expression in transduced PHFKs by RT-PCR for E6/E7 tran-
scripts and also by means of TP53 degradation by Western blot.
We observed no qualitative differences concerning TP53 degrada-
tion among all molecular variants analyzed. Furthermore, we
observed that parental keratinocytes or those infected with the
empty vector presented slower growth rates as compared to
transduced cells with the different molecular variants which
presented similar proliferation (data not shown).
Colony formation efﬁciency assay was conducted as described
previously (Halbert et al., 1991), by seeding cells at low density.
No colonies were observed for cells infected with the empty
vector (Table 2). Few colonies were observed when seeding
parental keratinocytes although cells in these colonies were
smaller as compared to those from infected PHFKs. Moreover,
cells from non-infected PHFKs were not able to overcome crisis
and senesced. Cells infected with the E-P variant generated less
colonies as compared to both E-350G and AA variants which
presented comparable colony formation efﬁciency. Overall, we
observed that the isolated clones of transduced PHFKs showed
some level of crisis at about passage 15, from which we believe
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isolated colonies senesced at passage 20. On the other hand all
colonies isolated from E-350G and AA infected cells yielded
immortalized cell lines. We observed that infected cells at p30
exhibited vigorous and constant growth and were a homogeneous
population of proliferating cells. For the reasons presented, we
considered these isolated cells as immortalized.
AA and E-350G keratinocytes present higher capacity for in vitro
transformation
We estimated the ability of transduced keratinocytes to form
colonies when seeded in semi-solid agar which is a reliable assay to
evaluate the transformation potential of cells (Hurlin et al., 1991).
Parental keratinocytes were unable to grow in semi-solid medium.
On the contrary, all HPV-16 E6/E7 transducing cells were capable of
forming colonies, still AA and E-350G variants presented higher
capacity as compared to E-P infected cells (Table 3).
Different cellular expression patterns among normal and transduced
PHFKs
In an attempt to understand the observed differences con-
cerning PHFKs immortalization by HPV-16 molecular variants, we
analyzed the expression proﬁle of 84 selected cellular genes
involved in transformation and tumorigenesis. We compared
transcripts from non-infected PHFKs at passage 4 and from pools
of 5 colonies from infected PHFKs with each molecular variant at
passages 5 and 30 in 3 independent experiments.
The majority of differences were observed when comparing
parental with infected cells as a result of HPV-16 E6/E7 expression
(Table 4). Among genes differentially expressed due to HPV-16
E6/E7 transduction, we observed that S110A4 and MDM2 genes
involved in cell cycle control were downregulated independently of
the passage and the variant tested. HPV-16 transduction also
impacted several genes involved in invasion and metastasis:
MMP2 (gelatinase A), SERPINE1, and MMP1 (collagenase 1) were
downregulated in infected cells. Expression of some genes was
clearly associated to passage number: the MTSS1 gene was down-
regulated among early passage infected cells (p5) independently of
the variant analyzed, and VEGFA, HTATIP2 and MMP9 were differ-
ently expressed in late passage (p30) infected PHFKs as compared to
parental cells. Interestingly, upregulation of IL8 and downregulation
of MAP2K1 were speciﬁcally detected in AA and E-350G infected
cells, respectively, in both passages analyzed. Moreover, down-
regulation of ITGA2 (integrina a 2) was associated to late passage
AA infected PHFKs, and upregulation of CHEK2 was solely detected
in late passage L83V E6/E7 expressing cells (AA and E-350G).Discussion
We evaluated the ability to immortalize and transform PHFKs
of three commonly detected HPV-16 variants: the E-P, AA, andTable 3
Soft agar colony formation assay. Parental and infected keratinocytes were seeded
in semi-solid medium for 20 days in triplicates, in three independent experiments.
Relative mean colony numbers of triplicates in comparison to PHFKs infected with
HPV-16 E-P E6/E7, arbitrarily deﬁned as the reference and set value 1.
exp 1 exp 2 exp 3
E-P 1.0 1.0 1.0
AA 7.0 4.0 2.2
E-350G 8.9 3.5 2.4E-350G. Seeding at low density, followed by isolation of indivi-
dual colonies and continuously passaging to p30 were used to
score for colony formation efﬁciency and immortalizing fre-
quency, respectively. Both L83V containing variants (AA and
E-350G) not only exhibited the highest number of colonies but
also all colonies isolated yielded immortalized cell lines. In
addition, both variants presented similar ability to form colonies
when grown independently of anchorage, and higher than that
observed for the E-P isolate.
Recently Richard et al. (2010) observed that HPV-16 AA
infected PHFKs were faster dividing than E-P infected cells whilst
using pools of transduced cells. Our results complement and
strongly substantiates the signiﬁcant data and conclusions of
Richard et al., 2010 attributing to L83V harboring variants a
higher oncogenic potential. Nevertheless, our approach is differ-
ent in some aspects, as follows: (1) Richard et al., 2010 pooled and
further grew as mass cultures G418 selected HPV-16 transduced
PHFKs until p65 when this mixture of individually infected cells
was considered immortalized. In contrast, we scored immortali-
zation as the number of isolated E6/E7 clones capable of con-
tinuously passaging until p30; (2) we additionally analyzed the
E-350G variant that harbors exclusively the E6 350T-G mutation
with the purpose of possibly ascribing to this variation functional
differences observed between the E-P and AA variants; (3) we
determined viral titers in the supernatant of packaging cells in
order to normalize for amounts of virus used to infect PHFKs, once
the production of viral particles can vary considerably between
cells infected with different constructs and affect the interpreta-
tion of the results.
In contrast to our data, inhibition of differentiation induced by
serum and calcium was similar among the E-P and AA variants,
whereas the E-350G variant showed higher levels of activity
(Asadurian et al., 2007). Nonetheless, resistance to differentiation
and immortalization can develop by two distinct processes
(Sherman and Schlegel, 1996). Overall, our data expands knowl-
edge regarding HPV-16 E6/E7 functional differences endorsed to
natural genome variability, and further highlights that enhanced
oncogenic potential that may be attributed to the L83V mutation.
An opposite relation between the cyclin-dependent kinase 2A
inhibitor (p16) and pRB expression has been described in carci-
noma cell lines (Li et al., 1994). pRB inativation by E7 from high
risk HPV types leads to p16 overexpression in cervical cancer and
thus has been employed as an useful marker of this neoplasia
(Klaes et al., 2002). The fact that p16 levels were higher in
infected keratinocytes independently of the passage and the
molecular variant analyzed further supports the reliability of this
methodology for our analysis. Among the 84 cancer-related genes
investigated, the expression of 8 genes was signiﬁcantly affected
by HPV-16 E6/E7 transduction (Po0.05): CDKN2A, ITGA4, MMP1,
MMP2, S100A, SERPINE1, FOS andMDM2. Enhanced ITGA4 (integrin
a4), and integrin a5, b3, b4, and b6 expression was formerly
observed in the epithelium during the development of cervical
cancer (Schadendorf et al., 1993; Werner et al., 2011). In contrast
to HPV-positive cancer cells in which the E6-dependent pathway
is required for TP53 degradation, the MDM2 protein (mdm2 TP53
binding homolog) binds to and downmodulates TP53 function in
normal HPV negative cells (Hengstermann et al., 2001; Traidej
et al. 2000). Accordingly, downregulation of MDM2 observed in
early and late passage HPV-16 infected PHFKs may not be
relevant to HPV associated carcinogenesis. MMP2 (gelatinase A)
activity is associated to tumor invasion and metastasis (Rhee and
Coussens, 2002). Although previous studies from our group also
observed downregulated transcription of MMP2 in PHFKs trans-
duced with E6E7 as compared to normal cells, Western blot
assays revealed similar protein levels in these cells (da Silva
Cardeal et al., 2006).
Table 4
Cellular gene expression patterns in PHFKs expressing E6/E7 of different HPV-16 molecular variants.
Up Up Up Up Up Up Down Down Down Down Down Down
Gene Pathway Ep5 Ep30 AAp5 AAp30 350p5 350 p30 Ep5 Ep30 AAp5 AAp30 350 p5 350 p30 a
CDKN2A p16 Cell cycle 3.4 1.9 3.4 2.8 2.8 2.8 b
ITGA4 Integrin A4 Adhesion 5.0 2.6 6.9 4.4 5.3 4.1 b
MMP1 Colagenase 1 Invasion 12.1 31.7 13.1 25.8 28.6 2.1 b
MMP2 Gelatinase A Invasion 3.6 13.4 1.9 9.9 2.5 4.1 b
S100A4 Invasion/cell cycle 6.3 12.8 6.0 13.4 7.9 10.5 b
SERPINE1 PAl1 Invasion 5.1 5.1 4.4 4.3 6.1 6.7 b
FOS Transc factor 10.4 4.2 3.6 1.6 9.2 4.9 b
MDM2 Cell cycle 2.5 1.7 2.1 1.8 2.6 1.5 b
MTSS1 Adhesion 4.8 1.7 3.4 1.4 3.6 1.3 p5
VEGFA Angiogenesis 1.2 2.2 1.2 2.2 1.1 2.8 p30
HTATIP2 Apoptose 1.4 1.9 1.5 2.6 1.1 2.4 p30
MMP9 Gelatinase B Invasion 1.2 2.5 1.0 1.8 1.4 1.5 p30
IL8 Angiogenesis 2.5 1.3 1.6 2.2 1.4 1.1 AA
MAP2K1 MEK Signal transduction 1.8 1.5 1.4 1.1 2.8 2.6 350
ITGA2 Integrina A2 Adhesion 1.3 1.4 1.3 2.2 1.0 1.1 AA p30
CHEK2 Cell cycle 1.5 1.3 1.4 2.0 1.3 2.3 AA/350 p30
Infected PHFKs at passages 5 and 30 were pooled and grown until conﬂuence. RNA was extracted, and cellular gene expression was explored using Human Cancer
PathwayFinderTM RT2 ProﬁlerTM PCR array (SuperArray Bioscience Corporation, Maryland, USA) in three independent experiments. Gene expression of non-infected PFHKs
at passage 4 was arbitrarily deﬁned as the reference and set value 1. Positive bold numbers indicate signiﬁcant increased expression levels (po0.05), whereas negative
bold numbers indicate signiﬁcant decreased expression levels (po0.05) as compared to non-infected PHFKs. Not bold, non statistically signiﬁcant data (p40.05).
a Passage or variant in which the differential gene expression proﬁle was observed as compared to parental PHFKs.
b Differential expression of these genes was observed for all tested HPV-16 variants and passages.
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to passage number and/or HPV-16 molecular variant. For
instance, the enhanced expression of VEGFA was observed only
among late passage infected keratinocytes. Not surprisingly, this
protein was previously associated with cervical disease progres-
sion (Kuemmel et al., 2009). Speciﬁc downregulation of IL8 was
detected in early and late passage keratinocytes transduced with
the AA HPV-16 variant. Inhibition of expression of this cytokine
was also described in HPV-5 and -8 transducing keratinocytes
Akgu¨l et al., 2010, whereas upregulation in HPV-16 positive
vulvar intraepithelial neoplasia (Santegoets et al., 2008).
Mitogen-activated protein (MAP) kinases consists of serine/
threonine-speciﬁc protein kinases that respond to extracellular
stimuli and modulates cellular activities including proliferation,
differentiation, and cell survival. MAP kinases are activated
through protein kinase cascades called ‘‘MAPK pathways’’: MAP
kinase kinase kinase (MKKK, MEKK or MAP3K), MAP kinase kinase
(MKK, MEK, or MAP2K) and MAP kinase are activated in sequence.
A link between HPV-16 E6 and MAPK signaling has been found.
It was shown that the E6-350G variant activates the MAPK
signaling through RAP1, as opposed to the E-P that stimulates
this pathway via RAS (Chakrabarti et al., 2004). Furthermore, it
was observed that the E-350G variant exhibited enhanced signal-
ing through the MAPK pathway compared to the E-P as shown
by higher levels of activated MAP2K and MAPK1. Supporting
this data, in our study we observed upregulation of MAP2K1
speciﬁcally in keratinocytes infected with the E-350G variant.
Once quantitative differences in activation of MAPK signaling
between E-P and E-350G variants correlated with differences in
cooperative cell transformation with other signaling pathways
(Chakrabarti et al., 2004), this pathway may play a fundamental
role in the elevated oncogenic potential attributed to this variant.
We also detected CHEK2 (CHK2 checkpoint homolog) upregu-
lation in late passage AA and E-350G E6/E7 transduced PHFKs.
The protein encoded by this gene is a protein kinase that isactivated in response to DNA damage and is involved in cell cycle
arrest in G1. Mutations in CHEK2 have been associated to
enhanced risk of breast and prostate cancer (Dong et al., 2003).
Further, a protein truncating-mutant that abolishes the kinase
activity of CHEK2 has been found in patients with Li–Fraumeni
syndrome (Vahteristo et al., 2002). Larger studies are required to
clarify the exact role of CHEK2 in E6 L83V harboring variants.
In summary, our data add relevant and original information
concerning the impact of HPV natural intratipic variability upon
immortalization and transformation. We observed that AA and
E-350G infected keratinocytes achieved enhanced efﬁciency in
colony formation assay and further had higher capacity for in vitro
transformation, as compared to E-P infected cells. Both variants
comprise the L83V mutation, suggesting that these effects could be
assigned to this substitution. This variant was previously associated
to risk for cancer progression is some but not all studies conducted
in Europe. AA variants that also harbor this mutation were also
associated to increased risk for viral persistence and cervical cancer
(Sichero and Villa, 2006). We further detected different expression of
CHEK2 and MAP2K1 in keratinocytes infected with E-350G and late
passage L83V harboring variants, which could explain, at least in
part, differences in oncogenic potential attributed to these HPV-16
variants. Further studies are clearly warranted to elucidate the
physiologic effects of the proteins found in this study to be
differentially expressed among distinct HPV-16 molecular variants
as to understand the possible role of these proteins in the pathogen-
esis of cervical carcinoma.Materials and methods
Cells
Primary human foreskin keratinocytes (PHFKs) were purchased
from Clonetics, NJ, USA, and were maintained in keratinocyte serum
L. Sichero et al. / Virology 432 (2012) 127–132 131free medium (KSFM), supplemented with 5 ng/ml epidermal growth
factor (EGF) and 50 mg/ml bovine pituitary extract (Invitrogen, CA,
USA). Bosc23 ecotropic and Am-12 amphotropic cells were main-
tained in Dulbecco’s Modiﬁed Eagle Medium supplemented with 10%
fetal bovine serum and antibiotics (D10).
Retroviral transduction
We cloned E6/E7 genes of the different HPV-16 molecular
variants into the pLXSN retroviral vector. 30 mg of each plasmid
were used to transfect ecotropic Bosc23 cells by eletroporation.
After 48 h, cell supernatants were used to transduce amphotropic
Am-12 cells in the presence of 10 mg/ml polybrene, and 48 h post
infection cells were selected with 500 mg/ml G418. Transfection of
Bosc23 to produce a transient virus stock followed by cross-
infection of this stock into Am-12 packaging line was conducted
in order to obtain high-titer retroviral supernatants. Viral stocks
were titrated by a NIH3T3 cells G418 resistant colony assay
(Ausubel et al., 2001). Equal amounts of virus (MOI¼10) were
used to infect PHFKs in passage 2, in three independent experi-
ments. Cells were selected in 200 mg/ml G418 for one week.
At this stage, colonies from each independent infection were
pooled and passaged 1:6 until p6. In this way, the triplicates were
maintained through passages. A heterologous retroviral promoter
was used to drive E6 and E7 expression to facilitate the normal-
ization of protein levels among the different infected PHFKs.
Immortalization assay
Immortalization was conducted as previously described
(Halbert et al., 1991). For colony formation efﬁciency analysis,
500 infected cells at passage 6 were seeded in 10 cm plates in
quadruplicate. After 14 days, two plates were stained with
hematoxilin for colony counting; the remaining two plates were
used to isolate individual colonies. Approximately 3 colonies from
each infection were isolated, totalizing 9 colonies from PHFKs
infected with each HPV-16 molecular variant. Isolated colonies
were independently and continuously passaged 1:6 until senes-
cence or passage 30 when these were considered immortalized.
Transduced cells were only grown as mass cultures on p5 or p30
when identical number of cells from different colonies were
mixed and grown until conﬂuence preceding RNA and/or protein
extraction, or transformation assay.
In vitro transformation assay
Five colonies from infected PHFKs with each molecular variant
at late passage 30 were pooled and evaluated for their ability to
form colonies in semi-soft agar medium. Non-infected keratino-
cytes at passage 3 were used as negative control. In a 24 well
plate, 5000 or 10,000 cells were mixed to semisolid medium 0.3%
LMP Agarose in KSFM (Invitrogen, CA, USA) and seeded on top of a
bed of 1% LMP Agarose, per well. These experiments were
conducted in triplicates. After 20 days, wells were documented
microscopically and cells were counted in each well using the
Image J software (http://rsbweb.nih.gov/ij/).
Analysis of cellular gene expression by quantitative RT-PCR
For this assay, ﬁve independent colonies from infected PHFKs
with each molecular variant at passages 5 and 30 were pooled
and grown until conﬂuence. RNA was extracted using RNAspin
Mini (GE Healthcare, Buckinghamshire, UK). cDNAs were synthe-
sized using the RT2First Strand kit (SuperArray Biosciences, MD,
USA) from 1 mg of RNA isolated from each culture. Polymerasechain reactions (PCR) were performed using the RT2 SYBR green
Master mix (SuperArray Bioscience Corporation, MD, USA) and
Human Cancer PathwayFinderTM RT2 ProﬁlerTM PCR array (Super-
Array Bioscience Corporation, MD, USA) in a ABI 7300 Real-time
PCR System (Applied Biosystems, CA, USA). Using this system we
evaluated the expression of 84 genes known to be involved in
human transformation and tumorigenesis. Besides, ﬁve house-
keeping genes (BM2, HPRT1, RPL13A, GAPDH and ACTB), RT
controls, and PCR controls are included in this array. Data analysis
was performed using the DDCt method with the support of an
analysis template provided by the SuperArray website (http://
www.superarray.com/manuals/pcrarraydataanalysis.xls) (Livak
and Schmittgen, 2001). Genes differentially expressed in infected
PHFKs that diverged by 42-fold compared with non-infected
cells and with Po0.05 are emphasized.References
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